A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Bispecific Antibody Goes to Hybrid
Immunotherapy Open Access
Bispecific antibody has being actively pursued in cancer immunotherapy. By binding to specific surface proteins on T cells or NK cells, bispecific antibodies recruit T cells or NK cells to close proximity of tumor cells and kill tumor cells. A number of bispecific antibodies with diverse formats have been developed and some of them already in clinical stages. In the study of "Her2-S-Fab bispecific antibody has potent cytotoxicity against Her2-expressing tumor cells", a novel format ofdoi:10.4172/2471-9552.1000123 fatcat:l2jgecrdsfa3ljnawbp52rseyu